PROSTATE CANCER CHEMOPREVENTION TRIAL

前列腺癌化学预防试验

• 批准号: 7605680
• 负责人: MAARTEN C BOSLAND
• 金额: $ 3.39万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605680
• 关键词: Characteristics; Chemoprevention; Chemopreventive Agent; Computer Retrieval of Information on Scientific Projects Database; Disease; Double-Blind Method; Failure; Frequencies; Funding; Grant; Institution; Malignant Neoplasms; Malignant neoplasm of prostate; Radical Prostatectomy; Randomized; Recurrence; Research; Research Personnel; Resources; Reverse Transcriptase Polymerase Chain Reaction; Risk; Source; Soy Proteins; United States National Institutes of Health; cancer cell; cancer recurrence; men

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this randomized, double-blind chemoprevention trial are to determine whether chemopreventive treatments with soy protein reduce or delay further rise in PSA in men that present with a PSA failure as the first sign of disease recurrence following radical prostatectomy for prostate cancer. A second objective is to determine whether chemopreventive treatment with soy protein delays prostate cancer recurrence following radical prostatectomy, as indicated by PSA failure in men who are at high risk for recurrrence because their cancers have unfavorable characteristics. The ability of soy protein to reduce the frequency of recurrence and the quantity of circulating prostate cancer cells detected by RT-PCR will be determined.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这项随机、双盲化学预防试验的目的是确定大豆蛋白化学预防治疗是否可以减少或延缓前列腺癌根治性前列腺切除术后 PSA 失败作为疾病复发第一个迹象的男性 PSA 的进一步升高。第二个目标是确定大豆蛋白化学预防治疗是否会延迟根治性前列腺切除术后前列腺癌的复发，正如由于癌症具有不利特征而具有高复发风险的男性 PSA 失败所表明的那样。将确定大豆蛋白降低复发频率的能力以及通过 RT-PCR 检测到的循环前列腺癌细胞的数量。